Bacil Pharma Reports Losses and Revenue Decline for Q2 2026

Revenue for the half-year fell to Rs 0.18 crore from Rs 1.06 crore.
The company shifted to a net loss of Rs 0.03 crore for the half-year period.

Reader Takeaway: Revenue contraction and emerging debt pressure signify a difficult period for the company's operational recovery efforts.

What just happened

Bacil Pharma Limited announced its standalone and consolidated unaudited financial results for the quarter and half-year ended September 30, 2026. The board approved these results following a review by the audit committee, with statutory auditors completing a limited review as required by SEBI regulations.

Why this matters

The financial results highlight a stark decline in performance compared to the same period in the previous year. The transition from a profit of Rs 0.68 crore in the first half of the previous year to a net loss of Rs 0.03 crore reflects operational challenges. Furthermore, the company reported consolidated borrowings of Rs 5.52 crore as of September 30, 2026, a significant change from the nil borrowing status reported on March 31, 2026.

Risks to watch

Investors should monitor the company's ability to stabilize its revenue streams. The emergence of debt on the consolidated balance sheet and the current loss-making trajectory are key factors that may impact liquidity and financial flexibility in coming quarters.

Context metrics

Consolidated cash and cash equivalents reached Rs 0.97 crore as of September 30, 2026, showing an increase from Rs 0.57 crore recorded at the end of March 2026. Despite the cash position, the sharp revenue decline remains the primary concern for stakeholders.